Physician profile
Thomas E Wanko
NPI 1407854144
$3,425.43
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $815 · 2021: $765 · 2022: $215 · 2023: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.35 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Nevro Corp. | $311.16 | 2022-2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $266.07 | 2019-2023 | Breztri |
| Merck Sharp & Dohme LLC | $238.09 | 2019-2023 | Keytruda, Dificid, Zerbaxa |
| Amgen INC. | $221.18 | 2019-2023 | Tezspire |
| Allergan, INC. | $165.23 | 2019-2020 | |
| Abbvie INC. | $160.80 | 2021-2023 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $160.22 | 2019-2021 | |
| Lilly USA, LLC | $147.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $140.59 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.44 | 2019-2023 | Tradjenta, Jardiance |
| Grifols USA, LLC | $121.38 | 2019-2023 | Prolastin-C Liquid |
| Pfizer INC. | $112.29 | 2020-2023 | |
| Amarin Pharma, INC. | $105.26 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $94.44 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.63 | 2019-2023 | Xifaxan |
| Astellas Pharma US INC | $49.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.09 | 2019-2023 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $44.45 | 2021 | |
| Sunovion Pharmaceuticals INC. | $42.66 | 2019 | |
| Inspire Medical Systems, INC. | $30.22 | 2023 | Inspire |
| Jazz Pharmaceuticals INC. | $27.30 | 2019-2020 | |
| Pharming Healthcare, INC. | $24.60 | 2023 | Ruconest |
| Biohaven Pharmaceuticals, INC. | $20.04 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.25 | 2021 | |
| Melinta Therapeutics, LLC | $17.72 | 2023 | Vabomere |
| Eisai INC. | $17.27 | 2021 | |
| Advanced Respiratory, INC | $16.04 | 2019 | |
| Medtronic USA, INC. | $15.80 | 2019 | |
| Abbott Laboratories | $14.87 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.78 | 2020 | |
| Philips North America LLC | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wanko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.